Compare AMBQ & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMBQ | ARVN |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 594.9M | 658.2M |
| IPO Year | N/A | 2018 |
| Metric | AMBQ | ARVN |
|---|---|---|
| Price | $80.28 | $7.84 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 19 |
| Target Price | ★ $42.20 | $15.05 |
| AVG Volume (30 Days) | ★ 876.5K | 790.3K |
| Earning Date | 05-12-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $262,600,000.00 |
| Revenue This Year | $41.81 | N/A |
| Revenue Next Year | $27.98 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $22.12 | $6.06 |
| 52 Week High | $85.72 | $14.22 |
| Indicator | AMBQ | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 70.86 | 23.97 |
| Support Level | $25.90 | $7.35 |
| Resistance Level | $85.72 | $8.22 |
| Average True Range (ATR) | 5.98 | 0.43 |
| MACD | -0.34 | -0.08 |
| Stochastic Oscillator | 74.59 | 2.99 |
Ambiq Micro Inc is a fabless semiconductor company that has developed technology based on a patented Sub-threshold Power Optimized Technology (SPOT) platform that significantly reduces the amount of power consumed by integrated circuits. It is a pioneer and provider of ultra-low power semiconductor solutions designed to address the significant power consumption challenges of general purpose and AI compute - especially at the edge.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.